BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16645950)

  • 1. Breast cancer proteomics by laser capture microdissection, sample pooling, 54-cm IPG IEF, and differential iodine radioisotope detection.
    Neubauer H; Clare SE; Kurek R; Fehm T; Wallwiener D; Sotlar K; Nordheim A; Wozny W; Schwall GP; Poznanović S; Sastri C; Hunzinger C; Stegmann W; Schrattenholz A; Cahill MA
    Electrophoresis; 2006 May; 27(9):1840-52. PubMed ID: 16645950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential radioactive proteomic analysis of microdissected renal cell carcinoma tissue by 54 cm isoelectric focusing in serial immobilized pH gradient gels.
    Poznanović S; Wozny W; Schwall GP; Sastri C; Hunzinger C; Stegmann W; Schrattenholz A; Buchner A; Gangnus R; Burgemeister R; Cahill MA
    J Proteome Res; 2005; 4(6):2117-25. PubMed ID: 16335957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance.
    Besada V; Diaz M; Becker M; Ramos Y; Castellanos-Serra L; Fichtner I
    Proteomics; 2006 Feb; 6(3):1038-48. PubMed ID: 16385476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways.
    Yang F; Foekens JA; Yu J; Sieuwerts AM; Timmermans M; Klijn JG; Atkins D; Wang Y; Jiang Y
    Oncogene; 2006 Mar; 25(9):1413-9. PubMed ID: 16261164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
    Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
    Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laser capture microdissection in comparative proteomic analysis of hepatocellular carcinoma.
    Wang HY
    Methods Cell Biol; 2007; 82():689-707. PubMed ID: 17586277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic analysis in human breast cancer: identification of a characteristic protein expression profile of malignant breast epithelium.
    Hudelist G; Singer CF; Pischinger KI; Kaserer K; Manavi M; Kubista E; Czerwenka KF
    Proteomics; 2006 Mar; 6(6):1989-2002. PubMed ID: 16470630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Two-dimensional gel electrophoresis profiles of human normal prostate cells successfully established by 2-DE coupled with laser capture microdissection].
    Li Q; Li YL; Yang XY; Zhang HY; Li HM; Li YL
    Zhonghua Nan Ke Xue; 2007 Dec; 13(12):1064-7. PubMed ID: 18284050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Screening for differentially expressed proteins in nasopharyngeal carcinoma by laser capture microdissection and proteomic analysis].
    Yi H; Cheng AL; Huang WG; Zhang PF; Li MY; Peng F; Li F; Li C; Chen ZC; Xiao ZQ
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 May; 33(5):375-83. PubMed ID: 18544839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic analysis of high-grade dysplastic cervical cells obtained from ThinPrep slides using laser capture microdissection and mass spectrometry.
    Gu Y; Wu SL; Meyer JL; Hancock WS; Burg LJ; Linder J; Hanlon DW; Karger BL
    J Proteome Res; 2007 Nov; 6(11):4256-68. PubMed ID: 17902640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identificating cathepsin D as a biomarker for differentiation and prognosis of nasopharyngeal carcinoma by laser capture microdissection and proteomic analysis.
    Cheng AL; Huang WG; Chen ZC; Zhang PF; Li MY; Li F; Li JL; Li C; Yi H; Peng F; Duan CJ; Xiao ZQ
    J Proteome Res; 2008 Jun; 7(6):2415-26. PubMed ID: 18433155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
    J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NanoLC-FT-ICR MS improves proteome coverage attainable for approximately 3000 laser-microdissected breast carcinoma cells.
    Umar A; Luider TM; Foekens JA; Pasa-Tolić L
    Proteomics; 2007 Jan; 7(2):323-9. PubMed ID: 17163580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.